HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma

Abstract Background Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO. Metho...

Description complète

Détails bibliographiques

Auteurs principaux:	Xianglai Xu, Sihong Zhang, Ying Wang, Yanjun Zhu, Jiajun Wang, Jianming Guo
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2023-05-01
Collection:	Cancer Medicine
Sujets:	heme oxygenase 1 immune checkpoint inhibitor renal cell carcinoma T‐cell dysfunction tyrosine kinase inhibitor
Accès en ligne:	https://doi.org/10.1002/cam4.5787
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!